Render Target: STATIC
Render Timestamp:
5/22/2026, 5:50:11 AM EDT
5/22/2026, 9:50:11 AM UTC
Commit: 7ed46ecc04b401f23a28df741b5078df405d23e4
Cell Signaling Technology Logo - Extra Large
View Featured Offers >>
1% for the planet logo
  1. Home /
  2. Research /
  3. Coming Soon: GMP-Grade* Recombinant Monoclonal Antibody Conjugates for Cell Therapy Manufacturing & QC

Coming Soon: GMP-Grade* Recombinant Monoclonal Antibody Conjugates for Cell Therapy Manufacturing & QC

Incorporate robust, flexible CAR-T Cell Enrichment and Detection into Your Manufacturing and QC Workflows

A graphical representation of the cell therapy manufacturing process, including steps for Cell Transduction, Cell Activation/Differentiation, Cell Expansion, Cell Enrichment, and Lot Release Testing. The last three steps are associated with solutions described on the webpage.

CST revolutionized preclinical CAR cell characterization with universal recombinant monoclonal antibodies specific to the ubiquitous Whitlow/218 and G4S linker sequences of scFv-based CARs. This innovation enabled scientists to use a single reagent for a variety of assays without the time or cost of developing anti-idiotype antibodies for every CAR construct.

When available, these trusted antibody conjugates, manufactured to be GMP-grade*, are intended to simplify enrichment of G4S linker CAR+ cells and increase productivity for in-process QC and lot release assays. When preclinical development teams use the same reagents, handoffs can be that much easier as programs advance to later stages.

A graphical representation of scfv-expressing CAR cells with CAR linker antibodies attached to magnetic beads and attracted to a magnet for cellular enrichment. CAR+ Cell Enrichment in Manufacturing

Coming soon: GMP-Grade* G4S Linker (E7O2V) Rabbit Monoclonal Antibody (Biotin Conjugate)

  • Enrich any G4S linker-containing CAR-T cell with one reagent
  • Biotin-conjugated antibodies are amenable to magnetic bead-based CAR-T cell enrichment on cell therapy manufacturing instrumentation
  • Standardize percent CAR-positive cells and mitigate issues associated with low transduction efficiencies
  • Coming soon: Reagents will be designed and manufactured to GMP-grade* reagent standards (Full GMP certification and commercial quantities are expected to be available mid-2026)

Graphical representation of an scfv-based CAR expressed on the cell surface and attached to a CAR linker antibody labeled with a fluorophore. CAR+ Cell Detection for Analytical QC

Coming soon: GMP-Grade* G4S Linker (E7O2V) Rabbit Monoclonal Antibody (PE Conjugate)

  • Detect any G4S linker-containing CAR-T cell with one reagent
  • Simplify in-process QC and lot release assays
  • PE-conjugated antibodies plug into your existing analytical QC workflows
  • Amenable to CAR+ cell detection in flow cytometry and FACS-based enrichment
  • Coming soon: Reagents will be designed and manufactured to GMP-grade* reagent standards (Full GMP certification and commercial quantities are expected to be available mid-2026)

Icon of two hands transferring an object from one hand to the other. Coming soon: Seamless Transfer from Preclinical to Clinical*
  • Smoother handoffs when the same GMP-grade* reagents are used in preclinical development as in manufacturing and QC
  • Save time when you don't have to qualify reagents for advanced process development

Icon of several antibody vials surrounded by circular arrows. Reagent Security and Supply Continuity
  • Upon GMP certification*, the products will follow a GMP-compliant process, with required documentation and a controlled chain-of-custody to ensure traceability
  • Recombinant monoclonal antibodies produced from a Master Cell Bank enable lot-to-lot consistency

* GMP-grade antibody reagents are under development and not currently available.  The currently-available pre-GMP antibody reagents are not yet validated for GMP, are for Research Use Only (RUO) and are not for use in clinical manufacturing stages. Full GMP-grade certification and commercial quantities are expected to be available mid-2026.